🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effects of Different MAP Targets on Ocular Perfusion and Optic Nerve Microvasculature During Rhinoplasty

RecruitingNAAges 18 Years - anyAllHitit University
NCT07832305 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This randomized controlled trial aims to evaluate the effects of two different mean arterial pressure (MAP) targets during controlled hypotension on ocular perfusion and optic nerve head microvasculature in patients undergoing elective rhinoplasty or septorhinoplasty. A total of 60 patients will be randomized in a 1:1 ratio to a target MAP of either 50-60 mmHg or 60-70 mmHg during general anesthesia. Intraocular pressure (IOP) will be measured at predefined perioperative time points, and estimated ocular perfusion pressure (OPP) will be calculated using simultaneous MAP and IOP measurements. Optical coherence tomography angiography (OCTA) will be performed preoperatively and postoperatively to assess changes in peripapillary, optic nerve head, and macular microvascular parameters. The primary objective is to compare changes in peripapillary vessel density between the two MAP target gro

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18-50 years * Scheduled for elective rhinoplasty or septorhinoplasty * American Society of Anesthesiologists (ASA) physical status I-II * Willing and able to provide written informed consent Exclusion Criteria: * History of glaucoma, retinal disease, optic neuropathy, or other significant ophthalmologic disease * Previous ocular surgery * High myopia * Uncontrolled hypertension, diabetes mellitus, or other serious systemic disease * ASA physical status III or higher * Development of severe intraoperative hemodynamic instability * Massive intraoperative bleeding * Inadequate OCTA image quality for analysis * Pregnancy * Refusal to participate or withdrawal of consent
💊

What it tests

  • Lower MAP Target Strategy (50-60 mmHg)
  • Higher MAP Target Strategy (60-70 mmHg)
📍

Where

1 site
Hitit university
Çorum, Turkey (Türkiye)
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy